PRAH PRA Health Sciences Inc

Price (delayed)

$161.78

Market cap

$10.44B

P/E Ratio

52.02

Dividend/share

N/A

EPS

$3.11

Enterprise value

$11.41B

Sector: Healthcare
Industry: Diagnostics & Research

Highlights

The company's equity rose by 36% YoY and by 12% QoQ
The quick ratio is up by 22% year-on-year
The stock's price to earnings (P/E) is 73% more than its last 4 quarters average of 30.1 and 20% more than its 5-year quarterly average of 43.5
The company's net income fell by 19% YoY and by 11% QoQ

Key stats

What are the main financial stats of PRAH
Market
Shares outstanding
64.54M
Market cap
$10.44B
Enterprise value
$11.41B
Valuations
Price to earnings (P/E)
52.02
Price to book (P/B)
7.02
Price to sales (P/S)
3.22
EV/EBIT
37.76
EV/EBITDA
26.3
EV/Sales
3.58
Earnings
Revenue
$3.18B
EBIT
$302.14M
EBITDA
$433.77M
Free cash flow
$360.4M
Per share
EPS
$3.11
Free cash flow per share
$5.69
Book value per share
$23.06
Revenue per share
$50.25
TBVPS
$29.8
Balance sheet
Total assets
$4.18B
Total liabilities
$2.7B
Debt
$1.47B
Equity
$1.48B
Working capital
$194.49M
Liquidity
Debt to equity
1
Current ratio
1.15
Quick ratio
1.07
Net debt/EBITDA
2.23
Margins
EBITDA margin
13.6%
Gross margin
27.3%
Net margin
6.2%
Operating margin
10.3%
Efficiency
Return on assets
5.1%
Return on equity
15.5%
Return on invested capital
18%
Return on capital employed
10.4%
Return on sales
9.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRAH stock price

How has the PRA Health Sciences stock price performed over time
Intraday
0.01%
1 week
4.44%
1 month
7.82%
1 year
80.36%
YTD
28.97%
QTD
5.51%

Financial performance

How have PRA Health Sciences's revenue and profit performed over time
Revenue
$3.18B
Gross profit
$868.6M
Operating income
$328.09M
Net income
$197.04M
Gross margin
27.3%
Net margin
6.2%
The net margin has contracted by 22% YoY and by 13% from the previous quarter
The company's net income fell by 19% YoY and by 11% QoQ
PRA Health Sciences's operating margin has decreased by 13% YoY and by 3.7% QoQ
PRA Health Sciences's operating income has decreased by 10% YoY

Growth

What is PRA Health Sciences's growth rate over time

Valuation

What is PRA Health Sciences stock price valuation
P/E
52.02
P/B
7.02
P/S
3.22
EV/EBIT
37.76
EV/EBITDA
26.3
EV/Sales
3.58
The stock's price to earnings (P/E) is 73% more than its last 4 quarters average of 30.1 and 20% more than its 5-year quarterly average of 43.5
PRAH's EPS is down by 18% year-on-year and by 11% since the previous quarter
PRAH's price to book (P/B) is 38% higher than its last 4 quarters average of 5.1 and 25% higher than its 5-year quarterly average of 5.6
The company's equity rose by 36% YoY and by 12% QoQ
PRAH's P/S is 53% above its last 4 quarters average of 2.1 and 46% above its 5-year quarterly average of 2.2
PRAH's revenue is up by 3.8% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is PRA Health Sciences business performance
PRA Health Sciences's return on equity has decreased by 31% YoY and by 18% QoQ
PRA Health Sciences's return on assets has decreased by 27% YoY and by 15% QoQ
PRAH's return on sales is down by 19% year-on-year and by 6% since the previous quarter
PRAH's return on invested capital is down by 18% year-on-year and by 3.7% since the previous quarter

Dividends

What is PRAH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRAH.

Financial health

How did PRA Health Sciences financials performed over time
The total assets is 55% greater than the total liabilities
The quick ratio is up by 22% year-on-year
The current ratio has grown by 19% YoY
The company's equity rose by 36% YoY and by 12% QoQ
The debt to equity has declined by 25% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.